#United States #Jupiter #Myosin Therapeutics #MT-125 #NCI Showcase

Myosin Therapeutics Selected for 2026-2027 NCI Investor Initiatives Showcase

Myosin Therapeutics, Inc., a cutting-edge biotechnology firm specializing in cancer therapies, has received a prestigious selection as part of the 2026-2027 National Cancer Institute (NCI) Investor Initiatives Showcase. This company is recognized for developing a new class of therapies aimed at manipulating the mechanics of cancer cells.

The NCI's determination of Myosin as one of only 30 companies included in this exclusive showcase follows a rigorous selection process that involved competitive reviews by over 70 private-sector investors and strategic partners. This initiative not only highlights emerging innovators in oncology but also provides insights into groundbreaking advancements across multiple sectors, including biopharmaceuticals, diagnostics, digital health, and medical devices.

Myosin's innovative approach revolves around targeting the molecular nanomotors and physical mechanisms that enable cancer cells to thrive, invade surrounding tissues, and survive in hostile environments. These methodologies present a differentiating factor within the oncology field.

Dr. Courtney Miller, the Chief Executive Officer and Co-Founder of Myosin Therapeutics, expressed excitement regarding the selection, which she referred to as a significant honor. “NCI has played a crucial role in our journey, especially as we advance our lead candidate, MT-125, a first-in-class non-muscle myosin inhibitor currently progressing through the NCI-supported Phase 1/2 STAR-GBM clinical trial. Their continued backing for our innovative strategy marks a thrilling time in our clinical program,” stated Dr. Miller.

MT-125 is a promising therapy, offering hope for individuals grappling with glioblastoma, a particularly aggressive form of brain cancer. It has recently been granted Fast Track designation by the FDA, along with Orphan Drug designation for malignant gliomas, hinting at its potential effectiveness and the urgent need for new therapeutic strategies in this challenging area of oncology.

The recognition in the NCI Showcase not only provides Myosin Therapeutics visibility but also presents key networking opportunities with potential investors and strategic partners at important industry events. The NCI will feature Myosin alongside other pioneering organizations in its forthcoming 2026–2027 Showcase Companies Book, underscoring the achievements and support that have characterized Myosin's journey to this point.

Beyond oncology, Myosin's innovative molecular nanomotor platform extends into therapeutic applications for central nervous system (CNS) disorders, emphasizing the versatility and broad impact of their research. Their second candidate, MT-110, is supported by the National Institutes of Health (NIH) and represents a unique asset targeting specific non-muscle myosin pathways within the CNS landscape.

In summary, Myosin Therapeutics stands at the forefront of revolutionizing cancer treatment through sophisticated and targeted therapeutic approaches. The combination of industry recognition, strong leadership, and innovative research positions the company as a beacon of hope in cancer care and beyond.

For further inquiries or information about Myosin Therapeutics, you can reach out via their contact email at [email protected]

Stay tuned as Myosin continues to make significant strides in the fight against cancer.